Navigation Links
Cell Therapeutics to Present at the ROTH Capital Partners 25th Annual Growth Stock Conference
Date:3/10/2013

SEATTLE, March 11, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that management will present at the ROTH Capital Partners 25th Annual Growth Stock Conference on Monday, March 18, at 2:30 p.m. Pacific/ 5:30 p.m. Eastern/ 10:30 p.m. Central European time at the Ritz-Carlton Laguna Niguel in Dana Point, CA. 

The presentation will also be webcast live and available for replay after the presentation.  The webcast can be accessed at www.celltherapeutics.com.

About Cell Therapeutics, Inc.

Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit the company's website at www.CellTherapeutics.com.

CONTACT:

Monique Greer
+1-206-272-4343
mgreer@ctiseattle.com

Ed Bell
+1-206-282-7100
invest@ctiseattle.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... June 29, 2015 Research ... the "Pharmaceutical Grade Sodium Chloride Market by Applications, ... report to their offering. The pharmaceutical ... CAGR of 6.9% between 2014 and 2019 in terms ... 690 KT by 2019. The report on ...
(Date:7/6/2015)... , July 6, 2015 Array ... was showcased this past weekend at the 2015 ... oral presentation.  At the meeting, data were shared ... from a 100-patient randomized Phase 2 expansion of ... cetuximab, an EGFR inhibitor, with or without the ...
(Date:7/6/2015)... July 6, 2015   Cepheid (Nasdaq: CPHD ... for its 2015 second quarter ended June 30, 2015 ... the market. The Company will host a ... July 23, 2015, to discuss the results.  To access ... http://ir.cepheid.com at least 15 minutes before the scheduled ...
Breaking Medicine Technology:Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4
... Confirm Robust Efficacy of CIMZIA, BOSTON, Nov. ... new,Phase III data from the RAPID 1 and ... Annual Scientific Meeting (ACR), which show,CIMZIA(R) (certolizumab pegol), ... Factor), given with methotrexate, is significantly,more effective than ...
... Fla., Nov. 7 A new analysis,presented today ... Evaluation Of Rosuvastatin) showed CRESTOR(R) (rosuvastatin calcium) 40,mg ... in four,patient populations at varying levels of risk ... subjects defined by the Framingham risk,assessment tool as ...
Cached Medicine Technology:CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 2CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 3CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 4CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 5CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 6CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 7CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 8New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 2New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 3New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 4New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 5New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 6
(Date:7/4/2015)... NY (PRWEB) , ... July 04, 2015 , ... Chronic ... 15% of chronic pain sufferers have pain located in the neck. Another 19% suffer ... the neck. Chiropractic literature suggests that 45% of American workers must deal ...
(Date:7/4/2015)... ... 2015 , ... Tyler Boden, Project Developer of Sullivan Solar ... the North American Board of Certified Energy Practitioners (NABCEP®), and is now a ... well established national certification organization for renewable energy professionals. Designation as a NABCEP ...
(Date:7/3/2015)... ... July 03, 2015 , ... Brendon ... 2nd creating a buzz of media attention. In an effort to spread the ... Tiffany Hendricks. , "These days many people are feeling overwhelmed by stress and ...
(Date:7/3/2015)... ... July 03, 2015 , ... Rheumatology ... 2015 Annual Conference , the premiere continuing education and networking event for ... SeaWorld in Orlando, Florida. Speakers include the leading rheumatology experts in immunology, ...
(Date:7/3/2015)... ... July 03, 2015 , ... Renowned rhinoplasty surgeon and Symposium ... 2016 Dallas Rhinoplasty Symposium . To be held from March 4th - 6th, the ... at the Westin Galleria Dallas. , Designed to take participants from the basic training ...
Breaking Medicine News(10 mins):Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3
... Customer ... for engagement rings before meeting the partner they hope to marry - or any partner, for ... (PRWEB) May 8, 2010 ... a tendency among single women to shop for an engagement ring before actually finding ...
... of heart disease doubled for nurses with high work pressures, ... high-pressure job can boost the risk of heart disease among ... studies have mainly looked at high-pressure jobs and men, but ... part in the Danish Nurse Cohort Study. The women were ...
... ... Fastrack is the leading supplier of software & ... Infusion Pharmacies & Home Health Care Agencies. Only Fastrack offers ... as one system encompassing virtually every clinical, operational and financial aspect ...
... ... Supply is participating in the effort to raise awareness of the serious and growing problem of ... ... almost 7 million children have asthma (Atlanta is ranked 47th among the 50 worst cities for ...
... ... focused on lapel pins, coins, key chains, medallions and other metal products. In addition to ... excellent resource for all things related to lapel pins, and an informal forum for discussions related ... (PRWEB) May ...
... , ... Communications, Inc. (AIM: FCOM) (the “Company”), a leading Midwest competitive local exchange carrier providing ... ... First Communications, Inc. (AIM: FCOM) (the “Company”), a leading Midwest competitive local exchange carrier ...
Cached Medicine News:Health News:Statistics Reveal Women Choose Engagement Rings Before Men 2Health News:Fastrack Acquires Prometheus Group Industry Leading HME Billing Service 2Health News:National Allergy Supply Celebrates Asthma Awareness Month 2Health News:Monterey Lapel Pin Company Continues Its Website Evolution 2Health News:Monterey Lapel Pin Company Continues Its Website Evolution 3Health News:First Communications, Inc. Announces Audited Results for the Year Ended December 31, 2009 2Health News:First Communications, Inc. Announces Audited Results for the Year Ended December 31, 2009 3Health News:First Communications, Inc. Announces Audited Results for the Year Ended December 31, 2009 4
Measures up to 152 mm in 1 mm increments and 6 inches in 1/32 inch increments. Deeply etched graduations and dull finish....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: